CDK12 and non-small cell lung carcinoma: Somatic alterations including EGFR, ALK, CDK12 were successfully identified, two of which are targetable by currently available drugs, these findings approved the usage of ctDNA for mutation detection and the potential targeted therapy in NSCLC patients receiving chemotherapy.